FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Go back to FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 200.05 +0.09 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.96 | 52 Week High | $333.65 | |||
| Open | $200.57 | 52 Week Low | $223.02 | |||
| Day High | $203.45 | P/E | 25.61 | |||
| Day Low | $199.06 | EPS | $7.81 | |||
| Volume | 837,294 | |||||
| Sagebrush Gold Ltd. (NASDAQ: SAGE) | Delayed: 8.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.68 | 52 Week High | $62.64 | |||
| Open | $8.68 | 52 Week Low | $26.28 | |||
| Day High | $8.68 | P/E | N/A | |||
| Day Low | $8.68 | EPS | $-0.94 | |||
| Volume | 346,488 | |||||
